Andlauer Healthcare Group (AND) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue rose 1.8% year-over-year to $159.6 million, driven by organic growth in Canadian logistics, distribution, and specialized transportation, offset by continued weakness in U.S. truckload operations.

• Canadian ground transportation revenue (excluding fuel) rose 8.5% year-over-year, with dedicated and last-mile up 10.2% and air freight forwarding up 5.1%.

• Logistics and distribution revenue increased 6.8% year-over-year, driven by pharmaceutical and biologics clients, despite lower consumer health product volumes.

• EBITDA reached $41.3 million, up 5.9% year-over-year, with EBITDA margin improving to a record 25.9%.

• US-based truckload businesses continued to face challenging conditions, impacting segment results.

Financial highlights

• Healthcare logistics segment revenue was $44.1 million, up 4.7% year-over-year.

• Specialized transportation segment revenue was $115.5 million, up 0.8% year-over-year.

• Operating income rose 9.6% to $23.8 million.

• Net income was $16.3 million ($0.41 per diluted share), up from $15.3 million ($0.36 per share) last year.

• Total revenue for the nine months ended September 30, 2024, was $482.2 million, up 0.7% year-over-year.

Outlook and guidance

• Canadian business expected to maintain robust, high single-digit growth into 2025, with focus on network expansion and efficiency.

• U.S. business has likely reached its trough; stabilization expected, with potential for growth in 2025 due to easier comps and strategic focus on higher-value segments.

• Q4 expected to see a modest seasonal bump, but not as pronounced as last year due to a large client onboarding in Q4 2023.

• Management noted a more active acquisition market with easing interest rates and highlighted readiness to pursue expansion opportunities with a strong balance sheet.

• Intention to maintain a quarterly dividend of $0.11 per share, subject to financial results and board discretion.